#NewAseBioMember | "AseBio represents a strategic community that drives biotechnology forward in Spain"

AseBio. What does your company's work bring to the table and what is its strength?

Isabel Huber. Succipro was founded as a spin-off from IISPV and the Universitat Rovira i Virgili with the goal of transforming scientific discoveries into real therapeutic solutions. The company emerged from the DIAMET research group at IISPV, based on a line of scientific excellence led by Dr. Sonia Fernández-Veledo and Dr. Joan Vendrell, which has been validated through publications in prestigious journals such as Nature Immunology and Cell Metabolism.

Our company develops innovative drugs for inflammatory and metabolic diseases, with a pioneering focus on succinate modulation as a therapeutic target. Our strength lies in scientific excellence, the ability to generate first-in-class therapies, and a strong commitment to safety and efficacy to improve patients’ quality of life.

AseBio. What is AseBio for you?

Isabel Huber. AseBio represents a strategic community that drives biotechnology forward in Spain. For Succipro, it is a key platform to connect with other stakeholders in the ecosystem, share knowledge, and give visibility to disruptive projects aimed at transforming the treatment of chronic diseases.

AseBio. When did you first hear about AseBio?

Isabel Huber.I first heard about AseBio during my time as a researcher, in the context of technology transfer initiatives. Since then, I have followed its evolution as a key reference in the biotech sector in Spain.

AseBio. What do you expect from being part of an association like AseBio?

Isabel Huber. We hope to strengthen our collaboration network with companies, research centers, and investors, as well as to participate in initiatives that promote innovation, internationalization, and access to funding. We also value AseBio’s role as a key interlocutor with public institutions to help drive policies that support the development of innovative therapies.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Isabel Huber. At Succipro, we are developing a therapy based on succinate modulation, an emerging therapeutic target with great potential in inflammatory diseases such as inflammatory bowel disease. Since this is a novel therapeutic mechanism, one of the biggest challenges we face is “building awareness.” For us, it is essential to communicate its clinical relevance clearly and rigorously to investors, regulators, and healthcare professionals. We need to build trust around this new therapeutic pathway by demonstrating its safety, efficacy, and unique value compared to existing treatments.

In addition, we face the usual challenges of the biotech sector: access to early-stage funding, regulation adapted to innovation, and the need to establish strategic collaborations to move toward clinical trials. At Succipro, we believe that the combination of solid science, effective communication, and smart partnerships will be key to overcoming these challenges and bringing our therapy to patients.